In the Claims:

(Currently Amended) A depot system, for delayed release of active substances
comprising gas-free liposomes having a membrane the liposomes comprising consisting of
saturated synthetic phosphatidyl cholines selected from one or more from the group
consisting of dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC)
and distearoyl phosphatidylcholine (DSPC),

cholesterol and/or derivatives with a percentage ranging from about 35 to about 50 mole-%,

cationic lipids selected from the group of 3-β-[N-(N',,N'-dimethylaminoethane)carbamoyl]cholesterol (DC-Chol), 3-β-[N-(N,,N'-dimethylaminoethane)carbamoyl]cholesterol (DAC-Chol), N-[1-(2,3-dimyristoyloxy)propyl]-N, N, N-trimethylammonium salt (DMTAP), N-[1-(2,3-dipalmitoyloxy)propyl]-N, N, N-trimethylammonium salt (DPTAP) and N-[1-(2,3-dioleoyloxy)propyl]-N, N, N-trimethylammonium salt (DOTAP) with a percentage ranging from 5 to 20 mole-% in the liposomal membrane, and

one or more selected active substances from the group consisting of protein and peptide active substances.

- 2. (Withdrawn) The depot system according to claim 1, wherein the cationic lipids are cationic in a pH-sensitive fashion and selected from one or more from the group consisting of histaminylcholesterol hemisuccinate (His-Chol) and morpholine-N-ethylamino cholesterol (Mo-Chol).
- 3. (Previously Presented) The depot system according to claim 1, wherein at least about 90% of the active substance is enclosed in the liposome and less than about 10% is outside the liposome.
- 4. (Previously Presented) The depot system according to claim 1, wherein the active substance is entrapped in the liposome and more than about 10% thereof is outside the liposome.
 - 5. (Previously Presented) The depot system according to claim 1, wherein the depot